Biocartis Group NV provided financial guidance for the fiscal year 2023. Building on the strong performance of 2022, the company expects to take a next significant step towards operating profitability, with: product related revenues of between EUR 55 million and EUR 60 million, reflecting growth of 25%-35% when excluding sales of SARS-CoV-2 tests that are expected to further decrease.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.29 EUR | +1.05% | -.--% | -.--% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-.--% | 29.6M | |
+73.35% | 12.42B | |
-19.45% | 7.81B | |
+3.71% | 6.4B | |
+13.65% | 5.45B | |
+38.48% | 5.01B | |
-17.79% | 4.84B | |
-19.78% | 4.19B | |
-29.00% | 2.69B | |
+45.41% | 2.39B |
- Stock Market
- Equities
- BCART Stock
- News Biocartis Group NV
- Biocartis Group Nv Provides Financial Guidance for the Fiscal Year 2023